Perseid Therapeutics LLC

23andme, Inc.

Maxygen, Inc.

Astellas Pharma Gmbh

Erik E Karrer

Steven Henry Bass

Juha Punnonen

Chingwei Vivian Lee

Sridhar Viswanathan

Madan M Paidhungat

Steven J Chapin

Margaret Neighbors

Germaine Fuh-Kelly

Yao-ming Huang

Louise Scharf

Yu Chen

Davide Foletti

Wei-Jen Chung

Christine Wolak

Steven J Pitts

Jilean Beth Fenaux

Cecilia Lay

Kristie Ibarra

Quan Zheng

Lindsay Deis

Dominic Samuel Berns

Robert Gerald Whalen

Tina Thai

Philip A Patten

Ashka Bharat Patel

Shashank Bharill

Brent R Larsen

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.

Anti-CD200R1 antibodies and methods of use thereof

The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.

Method of treating asthma with anti-IL1RAP antibodies

The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36α, IL-36β, and/or IL-36γ, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.

Anti-IL-36 antibodies and methods of use thereof

Anti-IL1RAP antibodies

The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.

Immunosuppressive polypeptides and nucleic acids

Methods for improving antibodies by a variety of DNA diversification and selection procedures are provided. Improvements include increases in affinity, alterations in specificity and effector function, as well as reduced antigenicity, e.g. humanization. Libraries of recombinant antibody sequences are provided, as are cells expressing members of such libraries. Novel phage display vectors are provided. Methods for the coevolution of an antibody and its cognate antigen are provided. Coevolution is used to evolve HIV envelope proteins with increased antigenicity and broadly neutralizing antibodies that interact therewith. Methods of improving antibodies for use in the detection of biological warfare agents are provided.

Antibody diversity generation

Growing community of inventors

Mountain View, CA, United States of America

Erik E Karrer